Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD11B1 | P28845 | 15/20 | 0.60 |
| ▸ | SLC6A3 | Q01959 | 3/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.41 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.41 |
| ▸ | CACNA1G | O43497 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10695332 | 0.91 | HSD11B1 (0.73) | HSD11B1SLC6A3SLC6A4SLC6A2CACNA1G | |
| SCHEMBL16232160 | 0.83 | HSD11B1 (0.83) | HSD11B1SLC6A3MEN1KMT2A | |
| SCHEMBL17761233 | 0.81 | HSD11B1 (0.60) | HSD11B1SLC6A3MEN1KMT2ASLC6A4 | |
| SCHEMBL1633828 | 0.79 | HSD11B1 (0.57) | HSD11B1SLC6A3MEN1KMT2ASLC6A4 | |
| SCHEMBL28271097 | 0.77 | OPRM1 (0.53) | HSD11B1SLC6A3 | |
| SCHEMBL627571 | 0.76 | HSD11B1 (0.90) | HSD11B1SLC6A3MEN1KMT2ASLC6A4 | |
| SCHEMBL4245329 | 0.76 | HSD11B1 (0.97) | HSD11B1SLC6A3MEN1KMT2ASLC6A4 | |
| SCHEMBL17761217 | 0.75 | HSD11B1 (0.66) | HSD11B1SLC6A3MEN1KMT2ASLC6A4 | |
| SCHEMBL10694536 | 0.75 | SLC6A4 (0.59) | HSD11B1SLC6A3SLC6A4SLC6A2 | |
| SCHEMBL17761311 | 0.75 | HSD11B1 (0.71) | HSD11B1SLC6A3SLC6A4SLC6A2CACNA1G |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150299184-A1 | Amine Derivatives as Potassium Channel Blockers | BIONOMICS LIMITED (AU) | 2015-10-22 | — | — | US | disclosed |
| US-20150299184-A1 | Amine Derivatives as Potassium Channel Blockers | BIONOMICS LIMITED (AU) | 2015-10-22 | — | — | US | disclosed |
| US-20140336198-A1 | Amine Derivatives as Potassium Channel Blockers | MERCK PATENT GMBH (DE) | 2014-11-13 | — | — | US | disclosed |
| US-20140336198-A1 | Amine Derivatives as Potassium Channel Blockers | MERCK PATENT GMBH (DE) | 2014-11-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140336198-A1 | Amine Derivatives as Potassium Channel Blockers | KCNA3, KCNH3, KCNK3 | HSD11B1 4199/4885SLC6A3 296/4885MEN1 1902/4885 |
| US-20150299184-A1 | Amine Derivatives as Potassium Channel Blockers | KCNA3, KCNH3, KCNK3 | HSD11B1 4199/4885SLC6A3 296/4885MEN1 1902/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.